Arthritis Innovation Corporation (AIC) has licensed a unique drug delivery system from Medincell (http://www.medincell.com/) comprised of the well-known biomaterials Poly-ethyleneglycol (PEG) and Poly-lactic acid (PLA). This injectable and biodegradable technology forms a semi-solid depot when exposed to an aqueous environment and can facilitate delivery of both hydrophobic and hydrophilic active pharmaceutical ingredients (API). The hydrophilic blocks can interact with hydrophilic APIs and enable their controlled release, whereas the hydrophobic blocks are able to solubilise and retain hydrophobic APIs. This technology is compatible with small molecules, peptides, proteins and antibodies. It can provide for controlled release with low or high burst effects, depending on the clinical need.